Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diabetes Diagnosis Clear all
Completed Phase 4 Interventional Results available

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

NCT03437044
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 24, 2026, 7:05 AM EDT
Recruiting No phase listed Observational

Genetics of Insulin and Incretins in Cystic Fibrosis

NCT01852448
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Blood or Saliva Sample Collection
Genetic
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus

NCT00633763
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
18F-fallypride
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Diabetes and Hypertension Self Management Program

NCT06034548
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
diabetes and hypertension self-management
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 24, 2026, 7:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Diabetes Staging System in Patient Aligned Care Teams

NCT06142006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2 Diabetes
Interventions
Diabetes Staging System (DSS) use among Primary Care Teams
Other
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
25 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk

NCT00915707
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Baseline, Sleep restriction, Reduced Sleep Quality
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Duration in Women With Previous Gestational Diabetes

NCT03638102
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Sleep extension, Healthy living
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 24, 2026, 7:05 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

NCT04684602
View directory record Official record
Conditions
Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease, Musculoskeletal Disorders, Neurodegenerative Disorders, Neurologic Disorders, Pulmonary Disorders, Sexual Dysfunction, Urologic Disorders, Viral Illness
Interventions
PrimePro™/ PrimeMSK™
Biological
Lead sponsor
Thomas Advanced Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Gestational Diabetes Diagnostic Methods

NCT01540396
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Dietary modification and medications
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

NCT04184622
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
54
States / cities
Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Does Access to an EHR Patient Portal Influence Chronic Disease Outcomes?

NCT00147706
View directory record Official record
Conditions
Congestive Heart Failure, Diabetes, Cardiovascular Disease
Interventions
Tailored Healthmedia programs on EHR Patient Portal
Procedure
Lead sponsor
Robert Wood Johnson Foundation
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Oct 24, 2026, 7:05 AM EDT
Recruiting No phase listed Observational

Drug Interaction Potential of Pro-Inflammatory Conditions

NCT07360938
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
Interventions
None (Observational)
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional

Self-Management and Glycemic Control in Adult Haitian Immigrants With Type 2 Diabetes

NCT04949568
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Patient Engagement, Patient Education
Interventions
Diabetes Self-Management Behaviors
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 24, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional

Texting for Diabetes

NCT03025984
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Texting
Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Multi-clinic Action Trial to Control Hyperglycemia and Hypertension

NCT02759484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Home Based Enhanced Education, Clinic Based Enhanced Education
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Cicero, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 24, 2026, 7:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers

NCT01693406
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Gestational Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 35 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 24, 2026, 7:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Peripheral Artery Genomics

NCT00615121
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

NCT02330549
View directory record Official record
Conditions
Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Cenicriviroc 150 mg, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Terminated Phase 4 Interventional Results available

Use of Sitagliptin to Decrease Microalbuminuria

NCT02048904
View directory record Official record
Conditions
Type 2 Diabetes, Microalbuminuria
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis

NCT02006342
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Insulin Glargine, Regular Insulin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 24, 2026, 7:05 AM EDT
Completed No phase listed Observational

Metabolic Phenotypes and Heterogeneity in Disease Burden Risk in Type 1 Diabetes

NCT05609279
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 24, 2026, 7:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Periodontal Disease on Outcomes in Diabetes

NCT02289066
View directory record Official record
Conditions
Periodontal Disease, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 24, 2026, 7:05 AM EDT
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 24, 2026, 7:05 AM EDT